Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.

Microbial and metabolic signatures, especially microbial metabolites like p-cresols and indoles, drive CNS autoimmunity severity in a mouse model of MS, with diet-microbiome interactions shaping disease outcomes.

• Why it matters: Understanding how gut microbiota and their metabolites influence MS progression is crucial because these factors are modifiable and could lead to new therapeutic strategies for this complex autoimmune disease.
• What they did: The study integrated microbiomic and metabolomic data from a longitudinal EAE mouse model, examining the effects of dietary tryptophan levels and L. reuteri colonization on microbiome composition and metabolite profiles, and their relation to disease severity.
• The result: Metabolites outperformed microbiota in predicting disease severity, with treatment using specific metabolites exacerbating EAE and neuroinflammation, highlighting potential targets for intervention and biomarkers for MS progression.